Clinical Trials Logo
  1. Home
  2. Advanced Malignant Solid Tumor
  3. NCT03662815

Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor

Advanced Malignant Solid Tumor Clinical Trial

Official title:
Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine inTreating Patients With Advanced Malignant Tumor

Clinical Trial Summary

This research study is evaluating a new type of cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for advanced malignant tumor. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of Chinese patients with advanced malignant cancer, so as to provide a new personalized therapeutic strategy for advanced pancreatic cancer patients. It is known that cancer patients have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the cancer to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03662815
Study type Interventional
Source Sir Run Run Shaw Hospital
Contact
Status Active, not recruiting
Phase Phase 1
Start date February 7, 2018
Completion date December 30, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04864379 - Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors Phase 1
Recruiting NCT04165590 - Plasmodium Immunotherapy for Advanced Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT05098405 - First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Phase 1
Recruiting NCT06150183 - Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05911984 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05396339 - A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. Phase 1/Phase 2
Recruiting NCT03171220 - Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors Phase 1/Phase 2
Recruiting NCT04241835 - A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function Phase 1
Not yet recruiting NCT06166472 - A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor Phase 1
Recruiting NCT05477849 - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors Phase 1
Not yet recruiting NCT04275050 - A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets Phase 1
Recruiting NCT04758897 - Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors Phase 1